GLUT-1 expression in ovarian carcinoma: Association with survival and response to chemotherapy

Guilherme Cantuaria, Anna Fagotti, Gabriella Ferrandina, Albino Magalhaes, Merhad Nadji, Roberto Angioli, Manuel Penalver, Salvatore Mancuso, Giovanni Scambia

Research output: Contribution to journalArticle

132 Scopus citations

Abstract

BACKGROUND. Cancer cell growth is an energy-related process supported by an increased glucose metabolism. The objective of this study was to investigate the association of GLUT-1 with response to chemotherapy and outcome in patients with ovarian carcinoma. METHODS. Histologic sections of formalin fixed, paraffin embedded specimens from 113 primary ovarian carcinomas were stained for GLUT-1 by using polyclonal GLUT-1 antibody (Dako Co., Carpinteria, CA) and the labeled streptavidin biotin procedure. Intensity of GLUT-1 staining was compared with disease free survival (DFS), chemotherapy response, and other clinicopathologic characteristics. RESULTS. GLUT-1 cytoplasmic membrane staining was observed in 89 of 104 (85.6%) malignant tumors. Poorly differentiated tumors showed a trend to overexpress the GLUT-1 protein compared with the more differentiated counterparts (27.6% vs. 8.7%; P = 0.08). Patients who experienced a complete clinical response to chemotherapy were more frequently GLUT-1 positive than GLUT-1 negative (80% vs. 51.5%; P = 0.036). In multivariate analysis of advanced stage disease, residual tumor (P = 0.0001) and high GLUT-1 expression levels (P = 0.028) were the only independent variables that maintained a significant association with response to chemotherapy (P = 0.0001; chi-square = 38.13). In the subgroup of Stage III-IV (International Federation of Gynecology and Obstetrics patients showing a complete clinical response, GLUT-1 overexpression was associated with a shorter DFS. The median time to progression was 30 months in GLUT-1 strongly positive cases (> 50% of cancer cells positive) versus 60 months in GLUT-1 weakly positive cases (≤ 50% of cancer cells positive; P = 0.024). CONCLUSIONS. GLUT-1 status is an independent prognostic factor of response to chemotherapy in advanced stage ovarian carcinoma. Moreover, patients overexpressing GLUT-1 show a significantly shorter DFS. These results suggest that the assessment of GLUT-1 status may provide clinically useful prognostic information in patients with ovarian carcinoma.

Original languageEnglish (US)
Pages (from-to)1144-1150
Number of pages7
JournalCancer
Volume92
Issue number5
DOIs
StatePublished - Sep 1 2001

    Fingerprint

Keywords

  • Chemotherapy
  • GLUT-1
  • Ovarian carcinoma
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cantuaria, G., Fagotti, A., Ferrandina, G., Magalhaes, A., Nadji, M., Angioli, R., Penalver, M., Mancuso, S., & Scambia, G. (2001). GLUT-1 expression in ovarian carcinoma: Association with survival and response to chemotherapy. Cancer, 92(5), 1144-1150. https://doi.org/10.1002/1097-0142(20010901)92:5<1144::AID-CNCR1432>3.0.CO;2-T